文献速递治疗药物监测与药物基因组学药物不良反应与药物警戒

基于DPYD基因型给药的氟尿嘧啶类治疗真实世界严重毒性影响

Optimizing fluoropyrimidine therapy: Real-world impact of DPYD genotype-based dosing on severe toxicity rates.
PubMed 文献 · Br J Clin Pharmacol · 2025-08-30

本研究为回顾性观察队列,纳入857例首次接受氟尿嘧啶类抗肿瘤治疗的成人患者,其中71例为DPYD变异等位基因携带者,按国际指南进行基因型给药。野生型患者严重毒性发生率27%,变异携带者为18%(P=0.11),提示按基因型给药后两组严重毒性发生率相当。

要点

  • 按DPYD基因型给药后,野生型与变异携带者严重毒性发生率相当(27% vs 18%,P=0.11)。
  • C.1236G>A携带者25%减量时aOR 0.63(95%CI 0.16-2.41),50%减量时aOR 0.39(95%CI 0.13-1.18)。
  • 与奥沙利铂联合多西他赛、奥沙利铂联合伊立替康及同步放疗是严重毒性的独立预测因素。

核心结论

  • 按DPYD基因型给药使野生型患者与DPYD变异等位基因携带者的严重氟尿嘧啶类相关毒性发生率相当。
  • 从毒性角度看,更新指南对C.1236G>A和C.2846A>T变异携带者的剂量推荐是合适的。
  • 研究结果强调需进行个体化剂量滴定,尤其是C.1236G>A变异携带者。

研究设计与样本

  • 回顾性观察性队列研究,在成人首次接受氟尿嘧啶类抗肿瘤治疗的患者中开展。
  • 共纳入857例患者,其中71例为DPYD变异等位基因携带者。
  • 对四个功能变异进行基因分型:DPYD*2A、C.1236G>A、C.2846A>T和DPYD*13,并按国际指南给药。

主要发现

  • 野生型患者严重氟尿嘧啶类相关毒性发生率为27%,变异等位基因携带者为18%(P=0.11)。
  • C.1236G>A携带者25%减量时aOR为0.63(95%CI 0.16-2.41),50%减量时aOR为0.39(95%CI 0.13-1.18)。
  • C.2846A>T携带者25%减量时aOR为2.00(95%CI 0.19-21.65),50%减量时aOR为1.18(95%CI 0.22-6.53)。
  • 严重毒性的显著独立预测因素包括联合奥沙利铂和多西他赛(aOR 10.67)、联合奥沙利铂和伊立替康(aOR 4.66)以及同步放疗(aOR 0.18)。

关键数值与推荐

  • 主要终点为严重氟尿嘧啶类相关毒性发生率,次要终点为识别其预测因素。
  • 基因分型覆盖DPYD*2A、C.1236G>A、C.2846A>T和DPYD*13四个功能变异。
  • 剂量调整按国际指南执行,分析中涉及25%和50%减量方案。

临床怎么用

  • 对接受氟尿嘧啶类治疗的患者应进行DPYD四个功能变异基因分型并按指南调整剂量。
  • C.1236G>A携带者需重点进行个体化剂量滴定以进一步降低毒性风险。
  • 联合奥沙利铂和多西他赛或伊立替康者应加强毒性监测。

局限性

  • 本研究为回顾性观察性设计,可能存在混杂与选择偏倚。
  • 变异携带者亚组样本量较小,部分aOR置信区间较宽。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Several international guidelines recommend DPYD genotype-based dosing in patients treated with fluoropyrimidines. This study evaluates the incidences of severe fluoropyrimidine-related toxicity between wild-type patients and DPYD variant allele carriers in a real-world patient cohort. METHODS: This retrospective, observational cohort study was conducted in adult patients with a first fluoropyrimidine-based anticancer therapy. Patients were genotyped for four function variants, DPYD*2A, C.1236G>A, C.2846A>T and DPYD*13. Dosing was according to international guidelines. The primary endpoint was the incidence of severe fluoropyrimidine-related toxicity. The secondary endpoint was to identify predictors for severe fluoropyrimidine-related toxicity. RESULTS: In total, 857 patients were included of which 71 were DPYD variant allele carriers. 27% of wild-type patients experienced severe fluoropyrimidine-related toxicity vs. 18% of variant allele carriers (P = 0.11). For C.1236G>A, the adjusted odds ratio (aOR) was 0.63 (95% confidence interval [CI] 0.16-2.41) following a 25% dose reduction, and 0.39 (95% CI 0.13-1.18) following a 50% dose reduction. For C.2846A>T, the aOR was 2.00 (95% CI 0.19-21.65) following a 25% dose reduction, and 1.18 (95% CI 0.22-6.53) following a 50% dose reduction. Significant independent predictors for toxicity were combination with oxaliplatin and docetaxel (aOR 10.67), oxaliplatin and irinotecan (aOR 4.66) and concurrent radiotherapy (aOR 0.18). CONCLUSIONS: DPYD genotype-based dosing resulted in comparable incidences of severe fluoropyrimidine-related toxicity between wild-type patients and DPYD variant allele carriers. The updated guideline recommendation on dosing of C.1236G>A and C.2846A>T variant carriers appears adequate from a toxicity perspective. Our findings highlight the need to perform an individual dose titration, especially in C.1236G>A variant carriers.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. van Kan AHE, Harmsze AM, Herbschleb K, et al. Optimizing fluoropyrimidine therapy: Real-world impact of DPYD genotype-based dosing on severe toxicity rates. Br J Clin Pharmacol. 2025. PMID: 40884356. doi:10.1002/bcp.70266

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。